Skip to main content

Jellagen

MaterialsStirling, UKFounded 2013· One of 916 Materials companies tracked by AMPulse

Develops and manufactures medical-grade Collagen Type 0 derived from jellyfish for bioprinting and tissue engineering, addressing risks of traditional mammalian sources.

CEO / Founder
Dr Andrew Spragg
Team Size
<50 employees
Stage
Active
Total Funding
£6.5M
Latest Round
Debt
Key Investors
dbw investments (3) ltd, Cardiff city region, MedCity Angels

Technology & Products

Key Products

Collagen Type 0 biomaterials; Cell culture scaffolds; Bioprinting hydrogels; Wound care materials

Technological Advantage

Evolutionary ancient collagen (Type 0) is compatible with a wide range of cell types and lacks the disease vectors found in mammalian collagen; ISO13485:2016-certified manufacturing facility.

Differentiation

Value Proposition

Provides a sustainable, non-mammalian 'Collagen Type 0' that offers an evolutionary ancient scaffold for tissue engineering while eliminating mammalian disease transmission risks associated with bovine or porcine sources.

How They Differentiate

Pioneer in non-mammalian biomaterials specifically for bioprinting; uses jellyfish collagen which is chemically simpler and safer than traditional mammalian sources.

Market & Competition

Target Customers

Universities, research laboratories, medical companies, biotech/pharma

Industry Verticals

Regenerative medicine; Tissue engineering; Wound care; Bioprinting; Scientific research

Competitors

CollPlant Biotechnologies (recombinant human collagen for bioprinting), Symatese (medical-grade collagen extraction and transformation), and Regenity (formerly Collagen Solutions, providing medical-grade collagen biomaterials).

Growth & Milestones

Growth Metrics

Turnover estimated £1.3M; Total funding raised >£6.5M.

Major Milestones

Founded in 2013; Launched 7,500 sq ft Cardiff facility in 2017; Achieved ISO13485 certification; Partnered with Copner Biotech in 2021 for bioprinting products; Share allotments in 2024

Notable Customers

Copner Biotech (3D bioprinting partner), Mayo Clinic (clinical development partner), and Thai Union Group (strategic manufacturing and investment partner).